Matthew Vincent Dolan, SVP Corporate Strategy-Develop at DEXCOM INC (DXCM), sold 5 shares at $81.63 ($408) on 2022-09-01, disclosed to the SEC on 2022-09-06.
Scheduled sale ($408) by SVP Corporate Strategy-Develop under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| DXCM | SELL | 2024-04-16 | $548K | — | Filing → |
| DXCM | SELL | 2024-03-19 | $1.1M | — | Filing → |
| DXCM | SELL | 2024-03-14 | $1.8M | — | Filing → |